Transdermal oxybutynin: a new treatment for overactive bladder

Area of Science:

• Urology
• Pharmacology

Background:

• Overactive bladder (OAB) is commonly treated with oral anticholinergic drugs, such as oxybutynin chloride.
• While effective for urinary incontinence, oral oxybutynin frequently causes side effects like dry mouth, leading to treatment discontinuation.
• N-desethyloxybutynin (N-DEO) is implicated in the anticholinergic side effects of oral oxybutynin.

Purpose of the Study:

• To evaluate the efficacy and tolerability of transdermal oxybutynin for managing overactive bladder symptoms.
• To compare the side effect profile of transdermal oxybutynin with oral formulations, focusing on dry mouth incidence.

Main Methods:

• A twice-weekly transdermal patch formulation of oxybutynin was utilized.
• The study assessed the maintenance of efficacy and reduction in adverse events compared to oral therapy.

Main Results:

• Transdermal oxybutynin maintains the therapeutic efficacy of oral oxybutynin in controlling incontinence.
• The transdermal route significantly minimizes anticholinergic side effects, notably dry mouth.
• Reduced hepatic and gastrointestinal metabolism via the transdermal route leads to lower N-DEO production.

Conclusions:

• Transdermal oxybutynin provides an effective and well-tolerated alternative for OAB management.
• This formulation improves patient adherence by mitigating common, therapy-limiting side effects.
• Transdermal oxybutynin represents a significant advancement in the treatment of urinary incontinence due to overactive bladder.